This year RNID have been chosen as the BIA’s charity partner of the year. This partnership gives us a unique platform to shine the light on the huge opportunities that exist for hearing therapeutics.
Getting UK clinical trials back on track - This second blog from the BIA conference, ‘The Future of UK Regulation: Driving innovation in the life sciences’, looks at what is being done across the research ecosystem to get commercial clinical trials back on track in the UK.
Altasciences is proud to support Alzamend Neuro in advancing their dementia treatment. They have completed a Phase IIa clinical trial in healthy subjects and are continuing to provide support in Alzheimer’s patients.
New antibody drug conjugate (ADC) programme unveiled, with demonstration of positive pre-clinical proof of concept for Myricx N-myristoyltransferase inhibitors (NMTi) as a completely novel ADC payload.
We were kindly hosted by Anthony Browne MP in the Terrace Pavilion of the House of Commons for a lunchtime reception where we launched our report ‘Becoming a life sciences superpower’ which includes our recommendations for the Comprehensive Spending Review (CSR) which has been confirmed by the Chancellor to be on the 27 October.
Clinical trials are an essential part of getting new treatments from lab to patient but during the COVID-19 pandemic, trials for treatments outside of COVID-19 had been heavily disrupted. However, in light of all this immediate disruption there have been claims that the swift action taken to produce a vaccine and the adoption of technology could set a positive precedent for the future of clinical trial research.
Per ICH GCP, Clinical Trial Monitoring is the act of overseeing the progress of a clinical trial, and of ensuring that it is conducted, recorded, and reported in accordance with the protocol, standard operating procedures (SOPs), GCP, and the applicable regulatory requirement(s).
